Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.
Mattia Alberto Di CivitaAndrea TorchiaDaniele SantiniDaniele MarinelliVirginia MagroMarianna CerroLaura PappalardoGiulia MalteseFiorenza SantamariaLuca ZaccoDorelsa BuccilliAilin DehghanpourIolanda SperanzaAlessandro SciarraValeria PanebiancoMichela RobertoPublished in: Current oncology (Toronto, Ont.) (2024)
The EV302 experimental arm showed better OS and PFS when compared to the other immunochemotherapy combinations. An immunochemotherapy combination strategy at the beginning of treatment in mUC seems to be superior in terms of OS and PFS compared to platinum-based chemotherapy alone. EV-Pembrolizumab resulted to have better outcomes compared to avelumab, rather than other immunochemotherapy combinations. However, given the heterogeneity of these studies, a longer follow up and prospective trials are needed to confirm these data.